Want to see KR:214390 full AI Analyst Report?
214390 Stock Chart & Stats
₩5140.00
-₩10.00(-0.19%)
―
--
Day’s Range― - ―
52-Week Range₩4,700.00 - ₩9,300.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)14.92K
Market Cap
₩122.88B
Enterprise Value₩267.53B
Total Cash (Recent Filing)₩13.83B
Total Debt (Recent Filing)₩158.00B
Price to Earnings (P/E)24.7
Beta0.06
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.97%
Share Statistics
EPS (TTM)N/A
Shares Outstanding23,906,860
10 Day Avg. Volume15,657
30 Day Avg. Volume14,919
Financial Highlights & Ratios
PEG Ratio-7.87
Price to Book (P/B)0.95
Price to Sales (P/S)0.52
P/FCF Ratio-4.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSteady revenue expansion indicates improving demand and/or pricing across the company’s pharmaceutical portfolio. If maintained, this broader top-line base can support operating leverage, strengthen commercial scale, and provide a foundation for more durable earnings improvement over coming quarters.
Gross Margin ImprovementThe substantial gross-margin improvement shows that the business is retaining more value from its sales than in earlier periods. This creates greater capacity to fund research, commercialization, and overhead, although sustained benefits depend on converting gross profit into stronger operating earnings.
Positive Operating Cash FlowPositive operating cash flow in most periods, including improvement to roughly 12.0bn in TTM, shows that the core business can generate internal cash before investment outlays. Maintaining this capability would help support operations and reduce reliance on external funding over time.
Bears Say
Persistent Negative Free Cash FlowRepeatedly negative free cash flow means operating cash has not covered investment and working-capital demands, limiting self-funded growth. The widening TTM deficit increases the company’s need for financing or balance-sheet support and could constrain investment if the pattern persists.
Rising LeverageDebt now exceeds equity on a trailing basis after a steady multi-year increase in leverage. Greater reliance on borrowing reduces financial flexibility, raises the importance of stable cash generation, and may limit the company’s ability to absorb weaker profitability or fund new initiatives internally.
Thin, Volatile ProfitabilityDespite stronger revenue and gross margin, only a small portion of sales currently reaches operating and net profit. The sharp fluctuation, including near-breakeven 2025 net profit, makes earnings less dependable and weakens the company’s ability to build equity or finance growth consistently.
Kyongbo Pharmaceutical Co., Ltd. News
214390 FAQ
What was Kyongbo Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Kyongbo Pharmaceutical Co., Ltd. lowest stock price was ₩4700.00 and its highest was ₩9300.00 in the past 12 months.
What is Kyongbo Pharmaceutical Co., Ltd.’s market cap?
Kyongbo Pharmaceutical Co., Ltd.’s market cap is ₩122.88B.
When is Kyongbo Pharmaceutical Co., Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Kyongbo Pharmaceutical Co., Ltd.’s earnings last quarter?
Currently, no data Available
Is Kyongbo Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Kyongbo Pharmaceutical Co., Ltd.’s price is currently Undervalued.
Does Kyongbo Pharmaceutical Co., Ltd. pay dividends?
Kyongbo Pharmaceutical Co., Ltd. pays a Annually dividend of ₩50 which represents an annual dividend yield of 0.97%. See more information on Kyongbo Pharmaceutical Co., Ltd. dividends here
What is Kyongbo Pharmaceutical Co., Ltd.’s EPS estimate?
Kyongbo Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kyongbo Pharmaceutical Co., Ltd. have?
Kyongbo Pharmaceutical Co., Ltd. has 23,906,860 shares outstanding.
What happened to Kyongbo Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kyongbo Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in KR:214390
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kyongbo Pharmaceutical Co., Ltd.
Established in 1987 and based in Asan, South Korea, Kyongbo Pharmaceutical Co., Ltd is a key player in the South Korean pharmaceutical market, primarily focusing on the production and distribution of active pharmaceutical ingredients (APIs). Its API offerings span general, cephalosporin, and anti-cancer categories. Beyond APIs, the company also supplies a range of finished pharmaceutical products, including prescription medications for anesthetic, cardiovascular, and digestive uses, as well as antibiotics, alongside its over-the-counter (OTC) drug portfolio. Kyongbo Pharmaceutical extends its reach internationally, exporting its goods to 30 countries worldwide. The company officially adopted its current name, Kyongbo Pharmaceutical Co., Ltd, in March 2002, having previously been known as Kyongbo Chemical Co. Ltd.
Technical Analysis
Dong Wha Pharm Co., Ltd.
―
Samil Pharmaceutical Co., Ltd.
―
SAMSUNG PHARMACEUTICAL.CO.,Ltd.
―
Jeil Pharmaceutical Co. Ltd.
―
Hana Pharm Co., Ltd.
―